Insider · CIK 0002052524
Douglas J Gentilcore
Files at YMAB (Y-mAbs Therapeutics, Inc.). First filing -, latest -.
In brief
Douglas J Gentilcore files SEC Form 4 as officer at YMAB (Y-mAbs Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Douglas J Gentilcore has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -142,600 | - | - | 0 | Sep 18, 2025 |
| Jan 17, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +142,600 | $0.00 | $0 | 142,600 | Jan 22, 2025 |
Questions about Douglas J Gentilcore
Answered from the filings on this page, as of the latest one.
Is Douglas J Gentilcore buying or selling?
Douglas J Gentilcore has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Douglas J Gentilcore's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Douglas J Gentilcore has 0.
Where does Douglas J Gentilcore file Form 4?
Douglas J Gentilcore has filed Form 4 at YMAB (Y-mAbs Therapeutics, Inc.) as SVP, Danyelza Bus. Unit Head. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.